News | August 14, 2024
Marksans Pharma Q1 FY25 revenue up 18%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
The partnership marks a significant milestone in integrating digital health education into medical curricula
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
Subscribe To Our Newsletter & Stay Updated
